BlossomHill Therapeutics, Inc. (NASDAQ: BLSM), a clinical-stage biopharmaceutical company developing small molecule cancer medicines, announced terms for its IPO on August 3, 2026. The San…
August 03, 2026
Latigo Biotherapeutics Sets Terms for $272 Million IPO, Backed by NEJM-Published Phase 2 Data for Its Non-Opioid Pain Candidate
Latigo Biotherapeutics, Inc. (NASDAQ: LTGO), a clinical-stage biopharmaceutical company developing oral, selective Nav1.8 inhibitors as non-opioid alternatives for acute and chronic pain, announced terms for…
Myriad Genetics, Inc. (NASDAQ: MYGN), a molecular diagnostics and precision medicine company, reported Q2 2026 financial results on July 30, 2026 that fell well short…
CareDx (NASDAQ: CDNA) raised its 2026 revenue guidance after reporting second-quarter results that exceeded expectations, driven by continued growth in its transplant diagnostics business and…
July 30, 2026
Viking Therapeutics (NASDAQ: VKTX): The Next Obesity Catalyst May Be About Staying on Therapy
Key Highlights Phase 3 enrollment for injectable VK2735 is complete, with maintenance dosing data expected later this quarter. Oral Phase 3 development remains on track…
Allogene Therapeutics has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for an allogeneic CAR‑T candidate in large B‑cell lymphoma. Early data show a disease…
July 29, 2026
Pulse Biosciences Hits Its Stride: NANOPULSE‑AF AFib Pivotal Trial Passes Enrollment Midpoint
The NANOPULSE‑AF study is evaluating the CellFX nano‑second pulsed field ablation (nsPFA) Cardiac Catheter System in people with drug‑resistant, symptomatic paroxysmal atrial fibrillation. The trial…
Corbus Pharmaceuticals received FDA clearance to start its TEMPO‑1 registrational trial. Registrational studies are designed to provide the pivotal data needed to support a future…
July 28, 2026
Atea’s Hepatitis C Breakthrough: New Short‑Course Pill Regimen Clears Phase 3 C‑BEYOND Trial
Phase 3 C‑BEYOND in hepatitis C met both primary and secondary goals. Atea’s pill combo bemnifosbuvir/ruzasvir showed very high cure rates and a solid safety…
Accuray Incorporated (NASDAQ: ARAY) is jumping today, with the stock up about 12% to 0.2529 from a prior close of 0.225. Shares have traded between…
July 28, 2026
Perspective Therapeutics Gains European Orphan Status for Targeted GEP‑NET Radiotherapy
Perspective Therapeutics (NYSE: CATX) received orphan medicinal product designation in Europe for its radiopharmaceutical candidate [212Pb]VMT‑α‑NET targeting gastroenteropancreatic neuroendocrine tumors (GEP‑NETs). Orphan status in the…
July 27, 2026
Capricor stock falls as FDA raises fresh questions
Capricor Therapeutics (NASDAQ: CAPR) came under pressure after the FDA released briefing documents ahead of the company’s July 29 advisory committee meeting for deramiocel, its…